Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo 90 mg/mL Clear all

Conditions: Pseudoachondroplasia
Interventions: resveratrol, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aging, Aging Well, Healthy Aging
Interventions: Nitrate enriched beetroot juice, Nitrate depleted beetroot juice, 12 week of combined exercise training; Dietary Supplement · Other
Lead sponsor: Florida Institute for Human and Machine Cognition; Other
Eligibility: 60 Years and older
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Postmenopausal Osteoporosis
Interventions: Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Gainesville, Georgia • Bethesda, Maryland

Conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Nephrectomy, Laparoscopic Donor Nephrectomy
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Catheter Occlusion, Thrombosis
Interventions: CUSA-081, Placebo, Alteplase; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more

Conditions: Acute Otitis Media
Interventions: amoxicillin-clavulanate, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Months to 23 Months
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers
Interventions: AV-1, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Shigellosis
Interventions: 240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
Interventions: Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 3 Days to 10 Days
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions: Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Renal Calculus, Kidney Stones
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions: High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Infertility
Interventions: GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more

Conditions: Postsurgical Pain
Interventions: CA-008, Placebo; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Pasadena, California • Carrollton, Texas • Houston, Texas + 1 more

Conditions: Cytomegalovirus Infection
Interventions: Placebo, Valganciclovir; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 4 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • St Louis, Missouri + 6 more

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Irvine, California • San Diego, California • Walnut Creek, California + 6 more

Conditions: Tendinopathy
Interventions: SM04755, Vehicle; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: West Nile Virus
Interventions: Omr-lgG-am, Polygam® S/D, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Glycemia
Interventions: Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Metabolic Syndrome X
Interventions: NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo; Drug · Device · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Newborn Hypoxic Ischemic Encephalopathy
Interventions: Melatonin, placebo; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 1 Hour to 8 Hours
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: Hepatorenal Syndrome, Acute Kidney Injury
Interventions: R2R01, Terlipressin; Drug
Lead sponsor: River 2 Renal Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Search by objective public record fields.

Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Acute Otitis Media (AOM) Therapy Trial in Young Children

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Cardiometabolic Consequences of the Loss of Ovarian Function

Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

TReatment for ImmUne Mediated PathopHysiology

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)

Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

IVIG - West Nile Encephalitis: Safety and Efficacy

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

Mechanisms of Cerebrovascular Control

Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome